MENU
+Compare
PACB
Stock ticker: NASDAQ
AS OF
Nov 13, 04:59 PM (EDT)
Price
$1.63
Change
-$0.12 (-6.90%)
Capitalization
525.32M

PACB Pacific Biosciences of California Forecast, Technical & Fundamental Analysis

Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems... Show more

Industry: #Biotechnology
PACB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for PACB with price predictions
Nov 12, 2025

PACB sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for PACB moved above the 200-day moving average on October 21, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PACB advanced for three days, in of 273 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 162 cases where PACB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for PACB moved out of overbought territory on November 03, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on November 06, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on PACB as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for PACB turned negative on November 05, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PACB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

PACB broke above its upper Bollinger Band on October 31, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PACB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (14.556) is normal, around the industry mean (63.534). P/E Ratio (0.000) is within average values for comparable stocks, (37.086). PACB's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.687). PACB has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.019). P/S Ratio (3.479) is also within normal values, averaging (79.919).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PACB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

View a ticker or compare two or three
PACB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

PACB is expected to report earnings to rise 27.33% to -15 cents per share on February 12

Pacific Biosciences of California PACB Stock Earnings Reports
Q4'25
Est.
$-0.15
Q3'25
Beat
by $0.03
Q2'25
Beat
by $0.04
Q1'25
Beat
by $0.04
Q4'24
Est.
$-0.20
The last earnings report on November 05 showed earnings per share of -11 cents, beating the estimate of -15 cents. With 3.89M shares outstanding, the current market capitalization sits at 525.32M.
A.I. Advisor
published General Information

General Information

a developer of sequencing system products to help scientists to resolve genetically complex problems

Industry MedicalNursingServices

Profile
Fundamentals
Details
Industry
Biotechnology
Address
1305 O’Brien Drive
Phone
+1 650 521-8000
Employees
796
Web
https://www.pacb.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PMDHX19.97N/A
N/A
Principal Small-MidCap Dividend Inc R6
RSPFX28.04-0.01
-0.04%
Victory RS Partners A
JBGCX60.77-0.07
-0.12%
JHancock Blue Chip Growth C
GSTOX21.36-0.03
-0.14%
Goldman Sachs Small Cap Gr Insghts Inv
RISRX14.15-0.03
-0.21%
RBC International Small Cap Equity R6

PACB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, PACB has been loosely correlated with ILMN. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if PACB jumps, then ILMN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PACB
1D Price
Change %
PACB100%
-6.45%
ILMN - PACB
48%
Loosely correlated
-0.51%
LAB - PACB
46%
Loosely correlated
-0.84%
AZTA - PACB
45%
Loosely correlated
+0.36%
CERS - PACB
44%
Loosely correlated
N/A
TWST - PACB
42%
Loosely correlated
+1.76%
More

Groups containing PACB

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PACB
1D Price
Change %
PACB100%
-6.45%
Medical/Nursing Services
industry (215 stocks)
36%
Loosely correlated
-2.32%
Health Services
industry (422 stocks)
-4%
Poorly correlated
-2.10%